Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 2/2016

01-02-2016 | Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Ethnic Minorities and Coronary Heart Disease: an Update and Future Directions

Authors: J. Adam Leigh, Manrique Alvarez, Carlos J. Rodriguez

Published in: Current Atherosclerosis Reports | Issue 2/2016

Login to get access

Abstract

Heart disease remains the leading cause of death in the USA. Overall, heart disease accounts for about 1 in 4 deaths with coronary heart disease (CHD) being responsible for over 370,000 deaths per year. It has frequently and repeatedly been shown that some minority groups in the USA have higher rates of traditional CHD risk factors, different rates of treatment with revascularization procedures, and excess morbidity and mortality from CHD when compared to the non-Hispanic white population. Numerous investigations have been made into the causes of these disparities. This review aims to highlight the recent literature which examines CHD in ethnic minorities and future directions in research and care.
Literature
1.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.CrossRefPubMed
2.
3.
4.•
Sardar M, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med. 2014;174:1868–70. An examination of RCTs which contributed to published guidelines which shows underrepresentation of women, minorities, and the elderly which may limit the generalizability of certain guidelines.CrossRefPubMed
5.
6.
7.
8.
Liao Y, Cooper RS, Cao G, Kaufman JS, Long AE, McGee DL. Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986 to 1994). J Am Coll Cardiol. 1997;30:1200–5.CrossRefPubMed
9.••
Rodriguez CJ, Allison M, Daviglus ML, Isasi CR, Keller C, Leira EC, et al. Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. Circulation. 2014;130:593–625. This is a comprehensive examination of cardiovascular disease in Hispanics in the USA. It not only describes traditional epidemiology concepts and risk factors but also touches on aspects of health and culture that are unique to Hispanics/Latinos.PubMedCentralCrossRefPubMed
10.
Sorlie PD, Avilés-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML, Giachello AL, et al. Design and implementation of the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol. 2010;20:629–41.PubMedCentralCrossRefPubMed
11.
Sempos CT, Bild DE, Manolio TA. Overview of the Jackson Heart Study: a study of cardiovascular diseases in African American men and women. Am J Med Sci. 1999;317:142–6.CrossRefPubMed
12.
Investigators TA. The atherosclerosis risk in communit (aric) stui)y: design and objectwes. Am J Epidemiol. 1989;129:687–702.
13.
Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41:1105–16.CrossRefPubMed
14.
Bild DE, Bluemke DA, Burke GL, Detrano R, Roux AVD, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871–81.CrossRefPubMed
15.•
Daviglus ML, Talavera GA, Avilés-Santa M, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA. 2012;308:1775–84. This paper not only describes the epidemiology of risk factors in Hispanics/Latinos but also highlights the considerable heterogeneity in this population.PubMedCentralCrossRefPubMed
16.
Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis. 2007;17:143–52.PubMed
17.
Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233–41.CrossRefPubMed
18.•
Jose PO, Frank ATH, Kapphahn KI, Goldstein BA, Eggleston K, Hastings KG, et al. Cardiovascular disease mortality in Asian Americans. J Am Coll Cardiol. 2014;64:2486–94. This study used a very large sample (10,442,034) to examine mortality rates in Asian Americans. The authors also detailed the significant differences between the extremely different groups which are lumped into the “Asian” classification.PubMedCentralCrossRefPubMed
19.
Sorlie PD, Backlund E, Johnson NJ, Rogot E. Mortality by Hispanic status in the United States. JAMA. 1993;270:2464–8.CrossRefPubMed
20.
Cortes-Bergoderi M, Goel K, Murad MH, Allison T, Somers VK, Erwin PJ, et al. Cardiovascular mortality in Hispanics compared to non-Hispanic whites: a systematic review and meta-analysis of the Hispanic paradox. Eur J Intern Med. 2013;24:791–9.CrossRefPubMed
21.
Abraído-Lanza AF, Dohrenwend BP, Ng-Mak DS, Turner JB. The Latino mortality paradox: a test of the “salmon bias” and healthy migrant hypotheses. Am J Public Health. 1999;89:1543–8.PubMedCentralCrossRefPubMed
22.
Ruiz JM, Steffen P, Smith TB. Hispanic mortality paradox: a systematic review and meta-analysis of the longitudinal literature. Am J Public Health. 2013;103:e52–60.PubMedCentralCrossRefPubMed
23.
Medina-Inojosa J, Jean N, Cortes-Bergoderi M, Lopez-Jimenez F. The Hispanic paradox in cardiovascular disease and total mortality. Prog Cardiovasc Dis. 2014;57:286–92.CrossRefPubMed
24.
Caleyachetty R, Echouffo-Tcheugui JB, Muennig P, Zhu W, Muntner P, Shimbo D. Association between cumulative social risk and ideal cardiovascular health in US adults: NHANES 1999–2006. Int J Cardiol. 2015;191:296–300.CrossRefPubMed
25.
Folsom AR, Yatsuya H, Nettleton JA, Lutsey PL, Cushman M, Rosamond WD, et al. Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol. 2011;57:1690–6.PubMedCentralCrossRefPubMed
26.
Dong C, Rundek T, Wright CB, Anwar Z, Elkind MSV, Sacco RL. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation. 2012;125:2975–84.PubMedCentralCrossRefPubMed
27.
28.
Kwagyan J, Retta TM, Ketete M, Bettencourt CN, Maqbool AR, Xu S, et al. Obesity and cardiovascular diseases in a high-risk population: evidence-based approach to CHD risk reduction. Ethn Dis. 2015;25:208–13.PubMedCentralPubMed
29.
Goff DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA) gender, ethnicity, and coronary artery calcium. Circulation. 2006;113:647–56.CrossRefPubMed
30.
Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168:598–608.CrossRefPubMed
31.
Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241–9.PubMedCentralCrossRefPubMed
32.
Guan W, Cao J, Steffen BT, Post WS, Stein JH, Tattersall MC, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:996–1001.CrossRefPubMed
33.
Daviglus ML, Pirzada A, Talavera GA. Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Prog Cardiovasc Dis. 2014;57:230–6.CrossRefPubMed
34.
Rodriguez CJ, Cai J, Swett K, González HM, Talavera GA, Wruck LM, et al. High cholesterol awareness, treatment, and control among Hispanic/Latinos: results from the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc. 2015;4:e001867.PubMedCentralCrossRefPubMed
35.•
Kershaw KN, Osypuk TL, Do DP, Chavez PJD, Roux AVD. Neighborhood-level racial/ethnic residential segregation and incident cardiovascular disease the Multi-Ethnic Study of Atherosclerosis. Circulation. 2015;131:141–8. This study goes beyond the usual examination of non-traditional risk factors and uses neighborhood segregation as an independent variable for cardiovascular disease.PubMedCentralCrossRefPubMed
36.
37.
de Souza RJ, Anand SS. Cardiovascular disease in Asian Americans: unmasking heterogeneity∗. J Am Coll Cardiol. 2014;64:2495–7.CrossRefPubMed
38.
Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95.PubMedCentralCrossRefPubMed
39.
Bild DE. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111:1313–20.CrossRefPubMed
40.
McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2006;113:30–7.CrossRefPubMed
41.•
Alluri K, McEvoy JW, Dardari ZA, Jones SR, Nasir K, Blankstein R, et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015;9:337–44.e1. This study uses a relatively new risk factor and describes disease patterns by race.CrossRefPubMed
42.
Will JC, Yuan K, Ford E. National trends in the prevalence and medical history of angina: 1988 to 2012. Circ Cardiovasc Qual Outcomes. 2014;7:407–13.PubMedCentralCrossRefPubMed
43.
44.
45.
Ford ES, Giles WH. Changes in prevalence of nonfatal coronary heart disease in the United States from 1971–1994. Ethn Dis. 2003;13:85–93.PubMed
46.
Cohen MG, Roe MT, Mulgund J, Peterson ED, Sonel AF, Menon V, et al. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE). Am Heart J. 2006;152:110–7.CrossRefPubMed
47.
Hayes DK, Greenlund KJ, Denny CH, Neyer JR, Croft JB, Keenan NL. Racial/ethnic and socioeconomic disparities in health-related quality of life among people with coronary heart disease, 2007. Prev Chronic Dis. 2011;8:A78.PubMedCentralPubMed
48.
Deshmukh M, Joseph MA, Verdecias N, Malka ES, LaRosa JH. Acute coronary syndrome: factors affecting time to arrival in a diverse urban setting. J Community Health. 2011;36:895–902.CrossRefPubMed
49.
Gillespie CD, Wigington C, Hong Y, Centers for Disease Control and Prevention (CDC). Coronary heart disease and stroke deaths—United States, 2009. Morb Mortal Wkly Rep Surveill Summ. 2013;62 Suppl 3:157–60.
50.
DeVon HA, Burke LA, Nelson H, Zerwic JJ, Riley B. Disparities in patients presenting to the emergency department with potential acute coronary syndrome: it matters if you are Black or White. Heart Lung J Acute Crit Care. 2014;43:270–7.CrossRef
51.
Movahed MR, Khan MF, Hashemzadeh M, Hashemzadeh M. Age adjusted nationwide trends in the incidence of all cause and ST elevation myocardial infarction associated cardiogenic shock based on gender and race in the United States. Cardiovasc Revasc Med. 2015;16:2–5.CrossRefPubMed
52.
Tataris KL, Mercer MP, Govindarajan P. Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database. Emerg Med J EMJ 2015.
53.
Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, et al. Persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study. Am Heart J. 2015;170:62–9.CrossRefPubMed
54.•
Cavender MA, Rassi AN, Fonarow GC, Cannon CP, Peacock WF, Laskey WK, et al. Relationship of race/ethnicity with door-to-balloon time and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: findings from get with the guidelines—coronary artery disease. Clin Cardiol. 2013;36:749–56. This study highlights persistent disparities in an important benchmark of CHD treatment quality. Despite the residual disparity, improvement in quality metrics was observed in all groups studied.CrossRefPubMed
55.
Curtis JP, Herrin J, Bratzler DW, Bradley EH, Krumholz HM. Trends in race-based differences in door-to-balloon times. Arch Intern Med. 2010;170:992–3.CrossRefPubMed
56.
Dauerman HL, Bates ER, Kontos MC, Li S, Garvey JL, Henry TD, et al. Nationwide analysis of patients with ST-segment-elevation myocardial infarction transferred for primary percutaneous intervention findings from the American Heart Association Mission: Lifeline Program. Circ Cardiovasc Interv. 2015;8:e002450.CrossRefPubMed
57.
Ayanian JZ, Udvarhelyi IS, Gatsonis CA, Pashos CL, Epstein AM. Racial differences in the use of revascularization procedures after coronary angiography. JAMA. 1993;269:2642–6.CrossRefPubMed
58.
Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs Medical System. N Engl J Med. 1993;329:621–7.CrossRefPubMed
59.•
Gaglia MA, Shavelle DM, Tun H, Bhatt J, Mehra A, Matthews RV, et al. African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention. Cardiovasc Revasc Med Mol Interv. 2014;15:214–8. This is a recent study that highlights that there is still an impact of race on the decision to use DES which can extend beyond other markers of socioeconomic status.CrossRef
60.
Batchelor WB, Ellis SG, Ormiston JA, Stone GW, Joshi AA, Wang H, et al. Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents. J Intervent Cardiol. 2013;26:49–57.CrossRefPubMed
61.
Cram P, Bayman L, Popescu I, Vaughan-Sarrazin MS. Racial disparities in revascularization rates among patients with similar insurance coverage. J Natl Med Assoc. 2009;101:1132–9.CrossRefPubMed
62.
Bhalla R, Yongue BG, Currie BP, Greenberg MA, Myrie-Weir J, DeFino M, et al. Improving primary percutaneous coronary intervention performance in an urban minority population using a quality improvement approach. Am J Med Qual. 2010;25:370–7.CrossRefPubMed
63.
Bangalore S, Gupta N, Guo Y, Feit F. Trend in the use of drug eluting stents in the United States: insight from over 8.1 million coronary interventions. Int J Cardiol. 2014;175:108–19.CrossRefPubMed
64.
Guzman LA, Li S, Wang TY, Daviglus ML, Exaire J, Rodriguez CJ, et al. Differences in treatment patterns and outcomes between Hispanics and non-Hispanic Whites treated for ST-segment elevation myocardial infarction: results from the NCDR ACTION Registry—GWTG. J Am Coll Cardiol. 2012;59:630–1.PubMedCentralCrossRefPubMed
65.•
Olafiranye O, Vlachos H, Mulukutla SR, Marroquin OC, Selzer F, Kelsey SF, et al. Comparison of long-term safety and efficacy outcomes after drug-eluting and bare-metal stent use across racial groups: insights from NHLBI Dynamic Registry. Int J Cardiol. 2015;184:79–85. This study describes a significant difference in outcome by race after the usage of DES. Further work will be needed to determine the precise cause of this difference.CrossRefPubMed
66.
Becker ER, Rahimi A. Disparities in race/ethnicity and gender in in-hospital mortality rates for coronary artery bypass surgery patients. J Natl Med Assoc. 2006;98:1729–39.PubMedCentralPubMed
67.••
Rangrass G, Ghaferi AA, Dimick JB. Explaining racial disparities in outcomes after cardiac surgery: the role of hospital quality. JAMA Surg. 2014;149:223–7. A large number of subjects (173,925) were used to provide convincing evidence that hospital quality is a major source of the disparities in outcomes between races. There is still a large fraction of the disparity in outcomes that remains unexplained.CrossRefPubMed
68.
Girotti ME, Shih T, Revels S, Dimick JB. Racial disparities in readmissions and site of care for major surgery. J Am Coll Surg. 2014;218:423–30.CrossRefPubMed
69.
Khera R, Vaughan-Sarrazin M, Rosenthal GE, Girotra S. Racial disparities in outcomes after cardiac surgery: the role of hospital quality. Curr Cardiol Rep. 2015;17:29.CrossRefPubMed
70.
Pollock B, Hamman BL, Sass DM, da Graca B, Grayburn PA, Filardo G. Effect of gender and race on operative mortality after isolated coronary artery bypass grafting. Am J Cardiol. 2015;115:614–8.CrossRefPubMed
71.
Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol. 2014;34:2644–50.PubMedCentralCrossRefPubMed
72.
Bray PF, Mathias RA, Faraday N, Yanek LR, Fallin MD, Herrera-Galeano JE, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost. 2007;5:1617–23.CrossRefPubMed
73.
74.
Carty CL, Keene KL, Cheng Y-C, Meschia JF, Chen W-M, Nalls M, et al. Meta-analysis of genome-wide association studies identifies genetic risk factors for stroke in African Americans. Stroke. 2015;46:2063–8.CrossRefPubMed
75.
76.
Kang H-J, Clare RM, Gao R, Held C, Himmelmann A, James SK, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015;169:899–905.e1.CrossRefPubMed
77.
Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, et al. Ticagrelor versus clopidogrel in black patients with stable coronary artery disease prospective, randomized, open-label, multiple-dose, crossover pilot study. Circ Cardiovasc Interv. 2015;8:e002232.CrossRefPubMed
78.
79.
80.
Burke JF, Vijan S, Chekan LA, Makowiec TM, Thomas L, Morgenstern LB. Targeting high-risk employees may reduce cardiovascular racial disparities. Am J Manag Care. 2014;20:725–33.PubMed
Metadata
Title
Ethnic Minorities and Coronary Heart Disease: an Update and Future Directions
Authors
J. Adam Leigh
Manrique Alvarez
Carlos J. Rodriguez
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 2/2016
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-016-0559-4

Other articles of this Issue 2/2016

Current Atherosclerosis Reports 2/2016 Go to the issue

Nonstatin Drugs (E. deGoma, Section Editor)

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

Cardiac Rehabilitation in Patients with Established Atherosclerotic Vascular Disease: New Directions in the Era of Value-Based Healthcare

Statin Drugs (B. Wiggins, Section Editor)

Women Versus Men: Is There Equal Benefit and Safety from Statins?

Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)

The Role of Ezetimibe in the Treatment of Cardiovascular Disease

Nonstatin Drugs (E. deGoma, Section Editor)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits